Astex featured in Biology Impacting Lives, an ITN Productions programme created in partnership with the Royal Society of Biology
Astex and Otsuka announce results of the Phase 3 ASCERTAIN study of oral cedazuridine and decitabine fixed-dose combination (ASTX727) in subjects with MDS and CMML
Learn more about the discovery and approval of Kisqali®
We’re a member of the Otsuka group of companies
Employment opportunities at our headquarters in UK and USA
